Download full-text PDF

Source
http://dx.doi.org/10.1002/bjs.1800700419DOI Listing

Publication Analysis

Top Keywords

tuberculosis hip
4
hip urinary
4
urinary fistulas--a
4
fistulas--a case
4
case report
4
tuberculosis
1
urinary
1
fistulas--a
1
case
1
report
1

Similar Publications

Tuberculous pyomyositis is an uncommon form of extrapulmonary tuberculosis (EPTB). We report a rare case of EPTB in a 34-year-old male post-renal transplant recipient. He presented with pain in the left hip region and fever 9 years after the renal transplantation.

View Article and Find Full Text PDF

Introduction: Obesity is a multifactorial disease caused by an interaction between genetic, environmental and behavioral factors. Polymorphisms of the two genes Circadian Locomotor Output Cycles Kaput (CLOCK) rs1801260 and Melanocortin-4-receptor (MC4R) rs17782313, are associated with obesity. Knowledge is limited on the interaction between CLOCK, MC4R and obesity.

View Article and Find Full Text PDF

Total hip arthroplasty in hip tuberculosis: a systematic review.

BMC Musculoskelet Disord

January 2025

Department of Joint Surgery, The Second Hospital of Jilin University, Changchun, 130,000, Jilin Province, China.

Objectives: Tuberculosis of the hip joint is a common form of bone tuberculosis that can cause severe joint destruction and affect quality of life. Total hip arthroplasty (THA) is an important way to treat hip joint-related diseases. In recent years, THA has been applied to treat tuberculosis of the hip joint and has achieved certain results.

View Article and Find Full Text PDF

Background: Anthropometric measurements used to predict cardiovascular disease vary worldwide but are mostly derived from those of Caucasian ancestry. We sought to undertake such measurements in the little studied Bangladeshi population.

Methods: The MAGPIE (Multidimensional Approach of Genotype and Phenotype in Stroke Etiology) study is a Bangladeshi stroke case-control study that recruited nationwide between January 2022 and June 2024.

View Article and Find Full Text PDF

Safety outcomes of tocilizumab and tofacitinib treatment for rheumatoid arthritis: Target trial emulation.

Int J Rheum Dis

November 2024

Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.

Objectives: Biological disease-modifying antirheumatic drugs have been the primary treatment option for moderate to severe rheumatoid arthritis (RA) in Taiwan since 2010. Tocilizumab is an interleukin-6 receptor inhibitor, whereas tofacitinib is a Janus kinase inhibitor. The two medications were indicated to treat RA by direct and indirect inhibition of interleukin-6 cytokine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!